Vanrx presented to the Parenteral Drug Association at their annual general meeting in Las Vegas, NV. The conference was well attended, with nearly 1,000 individuals from global industry and government gathering to learn about the latest technologies and perspectives of global regulators for the injectable drug industry. Vanrx CEO, Chris Procyshyn spoke to an audience of 250 and included individuals from FDA, the British MHRA, Genentech, Pfizer and Sanofi. Chris discussed other-industry approaches to process automation and error reduction, and where isolated robotic technology and the RAPTOR system can benefit manufacturers to reduce risk and increase process flexibility. Support was voiced from a number of the leading authorities in aseptic technology, and considerable interest and anticipation was indicated for a demonstration of Vanrx technology later this year at upcoming conferences in the United States and Europe.

Of particular significance to attendees this year was the topic of patient safety and revisiting of industry standards and their effects on infection rates. This topic of patient risk has been addressed with more priority and emphasis in the last two conferences this year, highlighting the trend toward overall risk reduction. The regulators globally are pushing for increased levels of patient protection, and increasingly new technologies are being pushed as the answer in lowering infection rates, and providing this quality without substantial increases in healthcare spending.

Posted in News